SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study

被引：0
|
作者：
Tongtong Wang
Shrita M. Patel
Anne Hickman
Xinyue Liu
Philip LStJ Jones
Ira Gantz
Carol E. Koro
机构：
[1] Merck & Co.,Department of Pharmacoepidemiology
[2] Inc.,Department of Clinical Safety and Risk Management
[3] Merck & Co.,Department of Global Clinical Development
[4] Inc.,Pharmaceutical Health Services Research, School of Pharmacy
[5] Safety Surveillance and Risk Management,undefined
[6] Pfizer Inc.,undefined
[7] Safety Surveillance and Risk Management,undefined
[8] Pfizer Inc.,undefined
[9] Merck & Co.,undefined
[10] Inc.,undefined
[11] University of Maryland,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Antihyperglycemic agents; Fournier’s gangrene; Nested case–control study; Sodium–glucose cotransporter 2 inhibitors (SGLT2i); Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：711 / 723
页数：12
相关论文
共 50 条
  • [21] Fournier's Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
    Chowdhury, Tutul
    Gousy, Nicole
    Bellamkonda, Amulya
    Dutta, Jui
    Zaman, Chowdhury F.
    Zakia, Ummul B.
    Tasha, Tasniem
    Dutta, Priyata
    Roy, Padmaja Deb
    Gomez, Adriana M.
    Mainali, Arjun
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [22] Fournier's gangrene under SGLT-2 inhibitor therapy: A literature review and case report
    Ellegard, Lisa
    Prytz, Mattias
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2020, 77 : 692 - 694
  • [23] Introducing SGLT2 inhibitors during hospitalization. Safety and outocmes
    Blasco Turrion, S.
    Camacho Jurado, F. J.
    Castilla Ortiz, R.
    Lobo Torres, I.
    Gomez Lopez, A.
    Collado Moreno, C.
    Gonzalez Perez, P.
    Sanchez Brotons, J. A.
    Casquero Dominguez, S.
    Martinez De Morentin, E.
    Maestre Garcia, M.
    Iravedra, M.
    Lozano Cid, J.
    Martinez Romero, P.
    Morales Ponce, F. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 151 - 151
  • [24] SGLT2 inhibitors increase the risk of diabetic ketoacidosis
    Reactions Weekly, 2016, 1603 (1) : 9 - 9
  • [25] HSA reviewing risk of ketoacidosis with SGLT2 inhibitors
    Reactions Weekly, 2015, 1574 (1) : 5 - 5
  • [26] Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis
    Abrahami, Devin
    D'Andrea, Elvira
    Kim, Seoyoung C.
    Wexler, Deborah J.
    Paik, Julie M.
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [27] Potential risk of encephalopathy syndrome with SGLT2 inhibitors
    Reactions Weekly, 2018, 1690 (1) : 3 - 3
  • [28] Impact of SGLT2 Inhibitors on the Risk of Postoperative AKI
    Song, Seungmin
    Kim, Minhyung
    Lee, Kyungho
    Jeon, Junseok
    Jang, Hye Ryoun
    Huh, Wooseong
    Lee, Jung Eun
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [29] SGLT2 inhibitors increase risk of diabetic ketoacidosis
    Reactions Weekly, 2017, 1656 (1) : 12 - 12
  • [30] Risk of serious rare infection with SGLT2 inhibitors
    Reactions Weekly, 2018, 1719 (1) : 2 - 2
12345